Effects of a combination of varenicline and nicotine patch on post-quitting urges to smoke Katie Myers Smith BSc MSc CPsychol Research Fellow Wolfson Institute.

Slides:



Advertisements
Similar presentations
Last updated November 2011 Efficacy of treatments for tobacco dependence treatobacco.net.
Advertisements

Produced in association with McNeil Products Limited – the makers of nicorette ® How we can get the most out of NRT: a review and update on nicotine replacement.
A Clinical Flow-Chart for the “Treatment-Resistant Smoker”
Pre-cessation nicotine treatment Jean-François ETTER Dr polit. sci, privat docent Institute de Médicine Sociale et Préventive Faculté de Médecine, Université.
ABCs of Behavioral Support Jonathan Foulds PhD. Penn State – College of Medicine
Treatment of Tobacco Dependence in 2012 J. Taylor Hays, MD Professor of Medicine Associate Director Nicotine Dependence Center Mayo Clinic Rochester, MN.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
Last updated December 2013  Efficacy of treatments for tobacco dependence treatobacco.net.
Nicotine Replacement Therapy: Administration and Overview Barbara Hart, MPA and Claudia Lechuga, MS Bronx BREATHES T: (718) E:
Prevention strategies
Smoking Cessation. Opportunity for Physicians 70 percent of smokers want to quit. Without assistance only 5 percent are able to quit. Most try to quit.
Treating Nicotine Dependence in Patients with Addictive Disorders Eric Heiligenstein, M.D. Director of Psychiatry University Health Services University.
Philip Tønnesen,2005 Smoking cessation Philip Tønnesen, M.D, Dr.med.sci.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence March–April 2015.
1 CTRI Webinar: Combination Medication Effectiveness June 9, 2010 Stevens S. Smith, Ph.D. Megan E. Piper, Ph.D. Center for Tobacco Research & Intervention.
Smoking cessation in New Zealand
Smoking Cessation Its place in Tobacco Control
BELLARMINE UNIVERSITY, LOUISVILLE, KY Electronic Cigarettes and Smoking Cessation Sarah Boone, Carolyn Little, Clay Owens, Jeremy Randolph, Genny Tibbs.
Quit Information Seminar. Aims of session To: help you to understand why people smoke provide information about quitting methods and products discuss.
ALCOHOL USE REDUCTION IN THE COURSE OF SMOKING CESSATION TREATMENT: A REVIEW Robert F. Leeman Stephanie S. O’Malley Yale University School of Medicine.
Real-world effectiveness of nicotine replacement therapy in pregnancy Leonie S. Brose, PhD Andy McEwen, PhD & Robert West, PhD University College London.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
An Updated Algorithm for Choosing Among Smoking Cessation Treatments John R. Hughes University of Vermont, USA
The Last Kiss An Internist’s Look at Smoking Cessation AIMGP 2007 Ken Locke MD, FRCPC.
ABSTINENCE AND RELAPSE AMONG SMOKERS WHO USE VARENICLINE FOR QUITTING—A POOLED ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Shade Agboola, Ann McNeill, Tim.
Laws/Policies ABSTRACT Problem: A challenge for tobacco control practitioners is getting smokers to quit using cessation methods. To increase the proportion.
Increasing Access to Pharmacotherapy Jonathan P. Winickoff, MD, MPH Associate Professor in Pediatrics Harvard Medical School April 26, 2013.
Nicotine dependence It’s in ICD 10! MRCPsych addiction psychiatry seminars March 2010.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Attempting to increase the use of smoking cessation medications Brendon Baker Ministry of Health.
Statistical analysis of pharmacotreatment effect and associated interactions in smoking cessation Dr Neil Walker, Oxford Biomedical Research Centre.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
-Tobacco is the leading preventable cause of disease, disability, and death in the United States (NIDA, 2012). -About 1 in every 5 deaths in the U.S. result.
1 Varenicline for smoking cessation Robert West University College London Logroño, October
Types of help Available NHS Stop Smoking Services Nicotine Replacement Therapy (NRT) Other Pharmacological Treatments (non nicotine) Alternative Therapies.
1 Recent studies of clinical significance University College London June 2011 Robert West.
Effectiveness of interventions to aid smoking cessation Robert West University College London September 2008.
Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.
1 Advising smokers on optimum pharmacotherapy for smoking cessation University College London April 2014 Robert West.
Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.
1 Cancer Research UK smoking cessation programme at UCL: Robert West University College London London October 2007.
What is the most we can achieve with behavioural support for smoking cessation? Robert West University College 1.
1 Products for smoking cessation University College London March 2014 Robert West.
1 Cytisine for smoking cessation Robert West John Stapleton Magda Cedzynska Paul Aveyard Witold Zatonski.
Hot topics in smoking cessation Robert West University College robertjwest 1.
1 Should behavioural support for smoking cessation address wider psychological problems? University College London October 2013 Robert West.
AN EXAMINATION OF THE PRACTICE OF TAILORING SMOKING CESSATION PHARMACOTHERAPY IN A TOBACCO TREATMENT PROGRAM WITHIN MENTAL HEALTH AND ADDICTIONS SETTINGS.
1 What does evidence-based behavioural support for smoking cessation look like? University College London UK Centre for Tobacco Control Studies National.
Pharmacotherapy for Smoking Cessation
Conclusions and Awards
Smoking Cessation Medication
6 myths and facts about tobacco use disorder in people with mental health and substance use disorders Associate Professor.
screening, brief intervention, and referral to treatment
Meta-analysis of Effectiveness of First-Line Smoking Cessation Pharmacotherapies 6 Months After Quitting Medication Estimated OR (95% CI) Est. abstinence.
Robert West University College London WCTOH Washington 2006
New Pharmacotherapies for Assisting Smokers in Their Cessation Efforts
Robert West University College London London March 2008
Behavioural and pharmacological approaches to treating smokers
Investigating factors which moderate the effectiveness of varenicline in clients using smoking cessation services in England Dr Neil Walker – Statistician,
Get smoker to their baseline for their behavioral health condition and initiating abstinence from substances. Then assess whether, in the past year, was.
Tobacco Cessation Guidelines for COPD
Forming a Tobacco Addiction
Smoking cessation Felix K. Karthik.
ABCs of Behavioral Support
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.
Hilary Millar, Val Reilly, Liz McGovern
Understanding the impact of the recession on smoking
Smoking Cessation.
Presentation transcript:

Effects of a combination of varenicline and nicotine patch on post-quitting urges to smoke Katie Myers Smith BSc MSc CPsychol Research Fellow Wolfson Institute of Preventive Medicine Queen Mary University of London

Disclosures The study was supported by an investigator- initiated grant from Pfizer, who also supplied varenicline. Nicotine and placebo patches were supplied by McNeil. The two pharmaceutical companies had no involvement in the design and conduct of the study, analysis and interpretation of the data, or preparation of the manuscript.

Current pharmacotherapy for smoking cessation Nicotine Replacement Therapy (NRT) Patch, gum, lozenge, inhaler, nasal spray, minis, mouth spray Bupropion Varenicline Evidence that patch + a rapid delivery form of NRT more effective than single NRT use 1 Combination of NRT recommended by The National Institute for Health and Clinical Excellence (NICE) 2 Evidence that patch + a rapid delivery form of NRT more effective than single NRT use 1 Combination of NRT recommended by The National Institute for Health and Clinical Excellence (NICE) 2 Insufficient evidence that bupropion + NRT increases long term abstinence 3 Combination not recommended by NICE 2 Insufficient evidence that bupropion + NRT increases long term abstinence 3 Combination not recommended by NICE 2 ? ? 1.Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD DOI: / C D pub Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD DOI: / CD pub3.

Combining NRT & varenicline: does it make sense? Both act on nAChRs (full and partial agonist) Both medications seem to achieve their effect on abstinence by alleviating the discomfort of nicotine withdrawal [1,2]. It is not clear if the central effects of the two medications are sufficiently different to allow synergy, but if they do differ, their combination could have some beneficial effects. 1. Stead LF, Perera R, Bullen C, Mant D, Lancaster T: Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008, 1, CD Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2011, 2, CD

Ebbert et al (2009) Observational cohort study Setting – inpatient smoking cessation facility Medications – NRT with/without varenicline, NRT with/without bupropion Results – no difference in outcome, no safety issues reported with combination treatment Currently no RCTs looking at varenicline+ NRT

Why it is important to do this research Increased number of dependent smokers Anecdotal clinical experience of benefit but needs to be experimentally investigated.

Study Aims To examine if there are differences between varenicline + nicotine patches varenicline + placebo patches In reduction of urges to smoke and withdrawal relief at 24hr and 1 week after quitting (primary endpoint) In short term abstinence rates (secondary endpoint)

Flow of participants Potential participants responding to adverts (n=514) Not invited to screening (n=234) - Not meeting inclusion criteria (n=72) - Did not want to participate (n=162) Not invited to screening (n=234) - Not meeting inclusion criteria (n=72) - Did not want to participate (n=162) Invited to screening/consent session (n=280) Attended screening/consent session (n=144) Not eligible (n=10) Randomised at TQD (n=117) Did not attend randomisation session (n=17) Allocated to placebo patch (n=59) Completed follow-up at 12-weeks post TQD (n=31) Allocated to nicotine patch (n=58) Completed follow up at 12-weeks post TQD (n=33) Measures Rating of urges to smoke and tobacco withdrawal symptoms (MPSS) Smoking status CO in expired breath(Lost to follow up = SMOKER) AEs recorded Measures Rating of urges to smoke and tobacco withdrawal symptoms (MPSS) Smoking status CO in expired breath(Lost to follow up = SMOKER) AEs recorded Abstinence endpoints Self reported abstinence at 24 hour phone call Continuous, validated abstinence at 1 week Russell Standard (up to 5 lapses allowed since TQD with validated report of no smoking at week 4) at 4 weeks post TQD Self reported abstinence at 12 weeks Abstinence endpoints Self reported abstinence at 24 hour phone call Continuous, validated abstinence at 1 week Russell Standard (up to 5 lapses allowed since TQD with validated report of no smoking at week 4) at 4 weeks post TQD Self reported abstinence at 12 weeks Patch use for 4 weeks Varenicline use for 12 weeks

Effect of combination on withdrawal No significant effect of combination treatment on urge to smoke or other withdrawal symptoms at 24 hour & 1 week post TQD

Abstinence *Self reported outcome Period after TQDPlacebo Patch (n=59) Nicotine patch (n=58) Pearson Chi- square; p value 24 hours80% (n=47)79% (n=46)0.00; p = week N (%)59% (n=35)69% (n=40)1.18; p = weeks N (%)59% (n=35)60% (n=35)0.01; p = week* N (%)29% (n=31)36% (n=33)0.73; p = 0.39

Adherence to medications There was no difference in adherence to medication between the two study arms at any time point. Adherence to the combination treatment during the crucial first week post TQD was high.

Adverse events No sig differences in ratings of nausea or any other AEs reported between the two groups at any time point AEs reported by more that 5% of participants included; - Abnormal dreams -Headache -Insomnia

Comments Adding nicotine patches to varenicline had no beneficial or detrimental effect on urges to smoke, withdrawal discomfort, abstinence rates, or adverse effects profile. Limitations; short-term follow up, small sample size

Patch use vs oral NRT use –short acting NRT (e.g. nasal spray) could be more effective. These products are typically under used as they require more effort from users, which would in theory reduce any benefit of combination treatment. Results from this study should be generalised to short acting NRT with caution.

No increase in nausea or any other AE was seen. Results suggest that this combination is well tolerated

Conclusion There is a widespread interest in combining NRT and varenicline in the hope of improving treatment outcomes. The results of this study suggest that such practice may not be productive or economical.

Publication Hajek, P., Myers Smith, K., Dhani, A., & McRobbie, H. (2013) Is a combination of varenicline more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Medicine. 11; /11/140

Acknowledgments The study randomisation was conducted by Mark Simmonds.

THANK YOU